Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model.


Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
09 2019
Historique:
received: 24 10 2018
revised: 22 01 2019
accepted: 25 02 2019
pubmed: 6 8 2019
medline: 8 8 2020
entrez: 6 8 2019
Statut: ppublish

Résumé

Immunotherapeutic approaches targeting amyloid β (Aβ) protein and tau in Alzheimer's disease and α-synuclein (α-syn) in Parkinson's disease are being developed for treating dementia with Lewy bodies. However, it is unknown if single or combined immunotherapies targeting Aβ and/or α-syn may be effective. Amyloid precursor protein/α-syn tg mice were immunized with AFFITOPEs® (AFF) peptides specific to Aβ (AD02) or α-syn (PD-AFF1) and the combination. AD02 more effectively reduced Aβ and pTau burden; however, the combination exhibited some additive effects. Both AD02 and PD-AFF1 effectively reduced α-syn, ameliorated degeneration of pyramidal neurons, and reduced neuroinflammation. PD-AFF1 more effectively ameliorated cholinergic and dopaminergic fiber loss; the combined immunization displayed additive effects. AD02 more effectively improved buried pellet test behavior, whereas PD-AFF1 more effectively improved horizontal beam test; the combined immunization displayed additive effects. Specific active immunotherapy targeting Aβ and/or α-syn may be of potential interest for the treatment of dementia with Lewy bodies.

Identifiants

pubmed: 31378574
pii: S1552-5260(19)30071-8
doi: 10.1016/j.jalz.2019.02.002
pmc: PMC7503212
mid: NIHMS1584449
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0
Immunologic Factors 0
alpha-Synuclein 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1133-1148

Subventions

Organisme : NIA NIH HHS
ID : R21 AG051839
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005131
Pays : United States
Organisme : BLRD VA
ID : I01 BX003040
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG018440
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG010483
Pays : United States

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Références

Mol Neurobiol. 2018 Mar;55(3):2653-2675
pubmed: 28421539
Mol Ther. 2014 Oct;22(10):1753-67
pubmed: 25008355
Acta Neuropathol. 2014;127(6):861-79
pubmed: 24525765
Hum Mol Genet. 2016 Mar 15;25(6):1100-15
pubmed: 26740557
Nat Rev Neurosci. 2013 Jan;14(1):38-48
pubmed: 23254192
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12245-50
pubmed: 11572944
J Neurosci. 2012 Jul 25;32(30):10253-66
pubmed: 22836259
Brain. 2016 Nov 1;139(11):2983-2993
pubmed: 27694152
Biochemistry. 2015 Mar 10;54(9):1831-40
pubmed: 25714795
J Neurosci Res. 2001 Nov 15;66(4):573-82
pubmed: 11746377
Acta Neuropathol. 2015 May;129(5):729-48
pubmed: 25758940
PLoS One. 2011;6(7):e22225
pubmed: 21779395
Hum Vaccin. 2010 Nov;6(11):948-52
pubmed: 20980801
PLoS One. 2010 Feb 19;5(2):e9313
pubmed: 20174468
J Neurosci. 2012 Sep 26;32(39):13454-69
pubmed: 23015436
Nat Med. 2015 Jul;21(7):802-7
pubmed: 26099047
Neurology. 2007 Mar 13;68(11):812-9
pubmed: 17353469
Neurology. 2004 Aug 10;63(3):554-6
pubmed: 15304594
J Neurosci. 2018 Jan 24;38(4):1000-1014
pubmed: 29246926
Acta Neuropathol. 2017 Aug;134(2):187-205
pubmed: 28401333
Acta Neuropathol Commun. 2017 Jan 5;5(1):2
pubmed: 28057080
Mol Neurodegener. 2015 Mar 19;10:10
pubmed: 25886309
J Neurosci. 2009 May 13;29(19):6132-41
pubmed: 19439591
Curr Alzheimer Res. 2016;13(1):18-29
pubmed: 26651341
PLoS One. 2015 Jan 22;10(1):e0115237
pubmed: 25611858
Neurology. 1990 Jan;40(1):1-8
pubmed: 2153271
Am J Pathol. 1998 Nov;153(5):1365-70
pubmed: 9811326
BMC Neurosci. 2011 Aug 03;12:79
pubmed: 21812967
Nat Rev Neurosci. 2013 Sep;14(9):626-36
pubmed: 23900411
Neurobiol Dis. 2017 Aug;104:85-96
pubmed: 28476636
Neuron. 2017 Jul 5;95(1):33-50
pubmed: 28683268
Am J Alzheimers Dis Other Demen. 2005 Sep-Oct;20(5):315-8
pubmed: 16273997
Brain. 2014 Jul;137(Pt 7):1958-70
pubmed: 24860142
J Neurochem. 2017 Mar;140(5):703-717
pubmed: 28027395
J Alzheimers Dis. 2018;61(3):1201-1219
pubmed: 29332037
Neurobiol Dis. 2018 Jan;109(Pt B):191-200
pubmed: 28359847
Biol Psychiatry. 2015 Nov 15;78(10):672-83
pubmed: 25676491
Neurochem Res. 2006 Sep;31(9):1153-62
pubmed: 16947080
J Neural Transm (Vienna). 2018 Apr;125(4):615-650
pubmed: 29222591
J Neurochem. 2013 Aug;126(4):473-82
pubmed: 23672786
J Neurosci. 2016 Jul 27;36(30):7971-84
pubmed: 27466341
Science. 2000 Feb 18;287(5456):1265-9
pubmed: 10678833
Cell Mol Neurobiol. 2017 Jan;37(1):121-131
pubmed: 26961542
Am J Pathol. 2013 Mar;182(3):940-53
pubmed: 23313024
J Neurosci. 2004 Oct 20;24(42):9434-40
pubmed: 15496679
J Parkinsons Dis. 2017;7(s1):S51-S69
pubmed: 28282814
Biophys Chem. 2017 Jan;220:34-41
pubmed: 27863716
Mov Disord. 2016 Feb;31(2):225-34
pubmed: 26388203
Mol Brain. 2017 May 30;10(1):18
pubmed: 28558799
Biochem Pharmacol. 2014 Apr 15;88(4):508-16
pubmed: 24462903
Brain. 2016 Dec;139(Pt 12):3217-3236
pubmed: 27679481
PLoS One. 2008 Sep 04;3(9):e3135
pubmed: 18769546
EMBO J. 2017 Sep 1;36(17):2473-2487
pubmed: 28768718
J Chem Neuroanat. 2015 Jan;63:1-5
pubmed: 25445382
J Alzheimers Dis. 2006;9(3 Suppl):417-23
pubmed: 16914880
J Neurosci. 2010 May 26;30(21):7281-9
pubmed: 20505094
PLoS One. 2014 Sep 11;9(9):e106883
pubmed: 25210774
J Neurosci Res. 2002 Jun 1;68(5):568-78
pubmed: 12111846
Neurotox Res. 2013 Jan;23(1):69-78
pubmed: 22610785
Neurology. 2006 Aug 22;67(4):660-5
pubmed: 16924019
Neurobiol Dis. 2014 Apr;64:107-17
pubmed: 24440055
J Prev Alzheimers Dis. 2015;2(2):103-114
pubmed: 29231230
Acta Neuropathol Commun. 2017 Dec 19;5(1):99
pubmed: 29258615
Adv Drug Deliv Rev. 2007 Sep 30;59(11):1093-102
pubmed: 17869376
J Neuropathol Exp Neurol. 2013 Dec;72(12):1203-12
pubmed: 24226269
Int J Geriatr Psychiatry. 2001 Mar;16(3):311-20
pubmed: 11288166
Acta Neuropathol. 2007 Sep;114(3):221-9
pubmed: 17653732
Mol Neurodegener. 2014 May 19;9:18
pubmed: 24885390
Mol Neurodegener. 2018 Mar 15;13(1):13
pubmed: 29544548
Science. 2003 Apr 25;300(5619):636-40
pubmed: 12714745
Brain Pathol. 2017 Jul;27(4):472-479
pubmed: 27495267
J Cereb Blood Flow Metab. 2013 Mar;33(3):330-8
pubmed: 23232947
Alzheimer Dis Assoc Disord. 2012 Jul-Sep;26(3):213-6
pubmed: 22037599
Anal Biochem. 2007 Aug 15;367(2):259-65
pubmed: 17597573
J Neurosci. 2010 May 5;30(18):6236-46
pubmed: 20445049
Alzheimers Res Ther. 2017 Jan 10;9(1):1
pubmed: 28073379
Neurotherapeutics. 2016 Jan;13(1):179-89
pubmed: 26494242
Sci Rep. 2016 Jun 29;6:28781
pubmed: 27352802
J Neurosci. 2009 Oct 28;29(43):13578-88
pubmed: 19864570
Ann N Y Acad Sci. 2000;924:62-7
pubmed: 11193803
J Vis Exp. 2014 Aug 25;(90):e51804
pubmed: 25177842
Neuron. 2006 Oct 5;52(1):33-8
pubmed: 17015225
Neurobiol Dis. 2009 Sep;35(3):415-25
pubmed: 19524671
J Neuroinflammation. 2016 Apr 07;13(1):74
pubmed: 27055651
PLoS One. 2011 Apr 29;6(4):e19338
pubmed: 21559417
Exp Neurol. 2012 Apr;234(2):405-16
pubmed: 22281106
J Mov Disord. 2016 Jan;9(1):14-9
pubmed: 26828212
Acta Neuropathol Commun. 2017 Jan 13;5(1):7
pubmed: 28086964
Neurobiol Dis. 2014 Sep;69:134-43
pubmed: 24851801
J Biol Chem. 2016 Aug 5;291(32):16485-93
pubmed: 27325705
Pharmacol Ther. 2013 Jun;138(3):311-22
pubmed: 23384597
J Neurosci. 2014 Jul 9;34(28):9441-54
pubmed: 25009275
Ann Neurol. 1999 Mar;45(3):353-7
pubmed: 10072050
J Neurosci. 2017 Oct 11;37(41):9808-9818
pubmed: 29021298
J Phys Chem B. 2016 Dec 22;120(50):12781-12794
pubmed: 27934063
Front Neurosci. 2017 Nov 29;11:667
pubmed: 29238289
Cell Rep. 2014 Jun 26;7(6):2054-65
pubmed: 24931606
Acta Neuropathol. 2018 Jan;135(1):33-47
pubmed: 29058121

Auteurs

Markus Mandler (M)

AFFiRiS AG, Vienna Biocenter, Vienna, Austria.

Edward Rockenstein (E)

Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.

Cassia Overk (C)

Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.

Michael Mante (M)

Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.

Jazmin Florio (J)

Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.

Anthony Adame (A)

Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.

Changyoun Kim (C)

Division of Neuroscience and Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA.

Radmila Santic (R)

AFFiRiS AG, Vienna Biocenter, Vienna, Austria.

Achim Schneeberger (A)

AFFiRiS AG, Vienna Biocenter, Vienna, Austria.

Frank Mattner (F)

AFFiRiS AG, Vienna Biocenter, Vienna, Austria.

Sabine Schmidhuber (S)

AFFiRiS AG, Vienna Biocenter, Vienna, Austria.

Gergana Galabova (G)

AFFiRiS AG, Vienna Biocenter, Vienna, Austria.

Brian Spencer (B)

Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.

Eliezer Masliah (E)

Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA; Division of Neuroscience and Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, USA; Department of Pathology, University of California, San Diego, La Jolla, CA, USA.

Robert A Rissman (RA)

Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA; VA San Diego Healthcare System, La Jolla, CA, USA. Electronic address: rrissman@ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH